Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Blood

Volumn 119, Issue 20, 2012, Pages 4597-4607

  Leonard, John P ^a   LaCasce, Ann S ^b,c   Smith, Mitchell R ^d   Noy, Ariela ^e   Chirieac, Lucian R ^c   Rodig, Scott J ^c   Yu, Jian Q ^d   Vallabhajosula, Shankar ^a   Schoder, Heiko ^e   English, Patricia ^f   Neuberg, Donna S ^g   Martin, Peter ^a   Millenson, Michael M ^d   Ely, Scott A ^a   Courtney, Rachel ^f   Shaik, Naveed ^f   Wilner, Keith D ^f   Randolph, Sophia ^f   Van Den Abbeele, Annick D ^b   Chen Kiang, Selina Y ^a   Yap, Jeffrey T ^b,c   Shapiro, Geoffrey I ^b,c   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BORTEZOMIB; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; RETINOBLASTOMA PROTEIN; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEART ARREST; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPH NODE BIOPSY; MALE; MANTLE CELL LYMPHOMA; METABOLISM; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84861210266     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388298     Document Type: Article

References (50)

1. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
2. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4): 511-518.
3. Kahl BS. Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents. Curr Hematol Malig Rep. 2009;4(4):213-217.
4. Smith MR. Should there be a standard therapy for mantle cell lymphoma? Future Oncol. 2011;7(2): 227-237.
5. Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol. 2011;80(1):69-86.
6. Leonard JP, Williams ME, Goy A, et al. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma. 2009;9(4): 267-277.
7. Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38.
8. Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 1984; 224(4656):1403-1406. (Pubitemid 14123338)
9. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A. 1991;88(21):9638-9642. (Pubitemid 21915686)
10. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res. 1992; 52(19 suppl):5541s-5544s.
11. Bosch F, Jares P, Campo E, et al. PRAD-1/Cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84(8):2726-2732. (Pubitemid 24317406)
12. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, Kluin PM, Schuuring E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 1995;10(9):1833-1840.
13. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750-762. (Pubitemid 47463673)
14. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770-1783. (Pubitemid 46628473)
15. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006; 108(5):1744-1750. (Pubitemid 44316145)
16. Dreyling MH, Bullinger L, Ott G, et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 1997;57(20):4608-4614. (Pubitemid 27441068)
17. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185-197. (Pubitemid 37443390)
18. Beà S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61(6):2409-2412. (Pubitemid 32685815)
19. Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood. 2003;101(8):3181-3187. (Pubitemid 36858013)
20. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol is untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21(9):1740-1745. (Pubitemid 46638586)
21. Tay K, Shapiro G, Disinski M, et al. Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) [abstract]. Proc Am Soc Clin Oncol. 2009;27: A8563.
22. Lacrima K, Valentini A, Lambertini C, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol. 2005;16(7):1169-1176. (Pubitemid 41418321)
23. Chen R, Chubb S, Cheng T, et al. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010;70(16):6587-6597.
24. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004; 3(11):1427-1438.
25. Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclindependent kinase 4/6. J Med Chem. 2005;48(7): 2388-2406. (Pubitemid 40516432)
26. Flaherty KT, LoRusso PM, DeMichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012; 18(2):568-576.
27. Schwartz GK, Lorusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862-1868.
28. Vaughn DJ, Flaherty K, Lal P, et al. Treatment of growing teratoma syndrome. N Engl J Med. 2009; 360(4):423-424.
29. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008; 49(suppl 2):64S-80S. (Pubitemid 351948037)
30. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30(12):908-917.
31. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
32. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13): 1773-1782. (Pubitemid 29512308)
33. Haddad RI, Weinstein LJ, Wieczorek TJ, et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004; 10(14):4680-4687. (Pubitemid 38955518)
34. Cheuk W, Wong KO, Wong CS, Chan JK. Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am J Surg Pathol. 2004;28(6):801-807. (Pubitemid 38685895)
35. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
36. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.
37. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107(8):3407.
38. Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49(5):439-451.
39. Wang L, Wang J, Blaser BW, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 2007;110(6): 2075-2083. (Pubitemid 47443925)
40. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004; 118(4):493-504. (Pubitemid 39485668)
41. Harada H, Nakagawa K, Iwata S, et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 1999;59(15):3783-3789. (Pubitemid 29381887)
42. Thoms HC, Dunlop MG, Stark LA. CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA. Cell Cycle. 2007; 6(11):1293-1297. (Pubitemid 47327959)
43. Herrmann K, Buck AK, Schuster T, et al. A pilot study to evaluate 3′-deoxy-3′-18F-fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52(12):1898-1902.
44. Menu E, Garcia J, Huang X, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 2008;68(14):5519-5523.
45. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66(15): 7661-7667. (Pubitemid 44289224)
46. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
47. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018-4032.
48. Konecny GE, Winterhoff B, Kolarova T, et al. Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer. Clin Cancer Res. 2011;17(6): 1591-1602.
49. Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010;18(1):63-73.
50. O'Dwyer PJ, Perini R, DeMichele A, et al. Phase I/II pharmacodynamic trial of PD0332991 in patients with KRAS mutant colorectal cancer [abstract]. Ann Oncol. 2011;22(suppl 3):PP01.